Cudetaxestat (BLD-0409), an experimental medication for idiopathic pulmonary fibrosis (IPF) from Blade Therapeutics, was well-tolerated among healthy volunteers…
Articles by Marisa Wexler, MS
Enrollment has been completed for INTEGRIS-IPF, a Phase 2a trial testing PLN-74809, an experimental oral anti-fibrotic therapy, in people with…
Treatment with either Ofev (nintedanib) or Esbriet (pirfenidone) — both antifibrotic therapies, but with different mechanisms of action…
Some people with so-called “long COVID” — breathlessness and other respiratory symptoms that persist long after the acute phase of…
Chiesi announced it has secured from UCB rights to zampilimab, a monoclonal antibody being investigated to treat idiopathic…
LYT-100 (deupirfenidone), an experimental oral therapy containing a similar active ingredient to Esbriet, was well-tolerated at all tested…
The American Thoracic Society (ATS) has premiered a docuseries called “Helping the World to Breathe,” showcasing the society’s commitment…
The National Institutes of Health (NIH) has awarded a grant to support research into immune mechanisms that could allow for…
Reviva Pharmaceuticals is planning to seek the U.S. Food and Drug Administration’s (FDA) permission to begin Phase 2 clinical…
Agomab Therapeutics and Origo Biopharma are joining forces to develop new therapies for pulmonary fibrosis (PF) and…